Filing Flows › Companies › Dogwood Therapeutics › Report card
Dogwood Therapeutics earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate3 of 4 reports beat the EPS estimate
Dogwood Therapeutics (DWTX) beat the analysts' EPS estimate in 3 of its last 4 reports (75%), by -11.1% on average.
Beat rate75% of 4
Average surprise-11.1%
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | Revenue reported |
|---|---|---|---|---|---|
| Q3 2026 | Nov 5, 2026 | −$0.15 | −$0.14 | +9.7% | $100K |
| Q to Jun 2026 | Aug 13, 2026 | −$0.14 | −$0.34 | -148.8% | — |
| Q to Mar 2026 | May 14, 2026 | −$0.20 | −$0.15 | +25.0% | — |
| Q to Dec 2025 | Mar 18, 2026 | −$0.86 | −$0.26 | +69.8% | — |
Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Dogwood Therapeutics: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.